Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. (PubMed, Lancet) - Sep 30, 2026 - P3 | "Treatment with retatrutide resulted in substantial improvements in bodyweight and was associated with improvements in glycaemic control in participants with obesity and type 2 diabetes, with a safety profile generally consistent with other molecules with GLP-1 receptor agonism. These results show that retatrutide might be effective for the treatment of obesity in people with type 2 diabetes."
Journal • P3 data • Diabetes • Genetic Disorders • Hypotension • Immunology • Metabolic Disorders • Obesity • Osteoarthritis • Pain • Respiratory Diseases • Rheumatology • Sleep Apnea • Sleep Disorder • Type 2 Diabetes Mellitus
|
|
Amanda Taylor; Carel W le Roux; Caroline Johnson; Elif I Ekinci; João Ferro; Juan P Frías; Kathryn Giblin; Petter Bjornstad; Sarah Eyde; So Young Park; Virginia Bellido
|